(19767 OCEANIC-AF) A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke

Prevention of stroke or systemic embolism in atrial fibrillation

Time to first occurrence of composite of stroke or systemic embolism, Time to first occurrence of ISTH major bleeding, Time to first occurrence of composite of stroke, systemic embolism, or ISTH major bleeding

Time to first occurrence of composite of ischemic stroke or systemic embolism, Time to first occurrence of all-cause mortality, Time to first occurrence of ischemic stroke, Time to first occurrence of cardiovascular (CV) death, Time to first occurrence of composite of CV death, stroke, or myocardial infarction, Time to first occurrence of composite of ISTH major or clinically relevant non-major bleeding, Time to first occurrence of clinically relevant non-major bleeding, Time to first occurrence of hemorrhagic stroke, Time to first occurrence of intracranial hemorrhage, Time to first occurrence of fatal bleeding, Time to first occurrence of minor bleeding, Time to first occurrence of composite of stroke, systemic embolism, ISTH major bleeding, or all-cause mortality, Time to first occurrence of composite of disabling stroke (modified Rankin Scale (mRS) >=3), critical bleeding, or all-cause mortality

No related papers found yet.

Papers published before 2008-02-04 may not appear yet. Historical indexing is in progress.

Austria, Belgium, Bulgaria, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden